The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex, to elicit a safe and durable anti-tumor response. In this video, Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, discusses TACTIC-2 (NCT04727151), an ongoing, Phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors. Preliminary results demonstrate the promising efficacy of this investigational therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.